雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

Brain and Nerve No to Shinkei Volume 35, Issue 9 （September 1983）

Brain and Nerve 脳と神経 35巻9号（1983年9月発行）

Japanese English

原著

悪性脳腫瘍に対するヒト線維芽球インターフェロンの効果—臨床およびヌードマウスにおける検討 ANTI-NEOPLASTIC EFFECT OF HU-IFN-β ON HUMAN MALIGNANT BRAIN TUMORS 中村治 ¹ , 寺本明 ¹ , 山本博昭 ¹ , 落合慈之 ¹ , 高倉公朋 ¹ , 丸尾幸嗣 ² , 上山義人 ³ , 島村和男 ³ Osamu Nakamura ¹ , Akira Teramoto ¹ , Hiroaki Yamamoto ¹ , Chikayuki Ochiai ¹ , Kintomo Takakura ¹ , Koji Maruo ² , Yoshito Ueyama ³ , Kazuo Shimamura ³ ¹東京大学脳神経外科 ²実験動物中央研究所 ³東海大学病理学 ¹Department of Neurosurgery, University of Tokyo Hospital ²Central Institute for Experimental Animals ³Department of Pathology, Faculty of Medicine, University of Tokai pp.905-911

発行日 1983年9月1日 Published Date 1983/9/1

DOI https://doi.org/10.11477/mf.1406205187

PDF(5875KB)

有料閲覧

Abstract 文献概要
1ページ目 Look Inside

　抄録　悪性脳腫瘍に文上するinterferon （IFN）治療として，①β—IFN，②IFN inducer （poly ICLC）投与を行ってきたが，その抗腫瘍効果を（1）基礎実験および（2）臨床経験に基づいて検討した。（1）β—IFN，poly ICLCのヌードマウスにおける抗腫瘍効果を従来の抗腫瘍剤と比較した。皮下にヒト脳腫瘍（2株）を移植したヌードマウスに対し，ACNU,vincristine, bleomycin,mitomycin C，β—IFN,poly ICLCを投与し，3週間後に腫瘍縮小効果をBattelle法で評価した。β—IFN,poly ICLCの効果はACNU,vincristineより若干劣ったものの，glioblastoma 1株では，β—IFN,43％，poly ICLC,39％（いずれも腫瘍／対照比）の効果がみられた。（2）臨床的に悪性脳腫瘍7例に対し，β—IFN 300万IU／日〜900万IU／日を2〜6カ月間にわたり投与し（4例，腫瘍内；3例，静脈内投与）効果および副作用を検討した。IFN腫瘍内投与4例中1例でCT scan上腫瘍縮小（PR）を認め，静脈内投与3例は不変であった。副作用については，腫瘍内投与例では，1例で発熱がみられた他は特記すべき副作用を認めなかったのに対し，静脈内投与例では，発熱，全身倦怠感，白血球減少，血小板減少などが認められた。

Since 1980, phase 1 and 2 clinical trials of Hu-IFN-β have been done in the field of neurosurgery. In the present study, (1) the results of in vivo ex-periments of Hu-IFN-β are reported and (2) the effectiveness of Hu-IFN-13 in patients with malig-nant brain tumors is also evaluated.

(1) The antitumor activities of β-IFN and poly ICLC in nude mice receiving subcutaneous transplants of human brain tumors (2 strains) were compared with those of conventional anticancer drugs. After 3 weeks of treatment with ACNU, vincristinc, bleomycin, mitomycin C, β-IFN and poly ICLC, tumor reduction rates were evaluated by the method of Battelle. The effectiveness of β-IFN and poly ICLC was slightly inferior to that of ACNU and vincristine, although tumor reduc-tion rates (treated/control values) of 43% and 39% were respectively obtained with β-IFN and poly ICLC against one strain of glioblastoma.

(2) Clinically, 7 patients with malignant brain tumors were given β-IFN (4 by intratumor admi-nistration and 3 by intravenous injection) in a dose of 3×10⁶ to 9×10⁶ IU/day for 2 to 6 months to study the efficiency and side effects of IFN treat-ment. One of four patients given IFN intratumor-ally showed a reduction in tumor size (partial response) by CT scan ; the three patients injected IFN intravenously were unchanged. There were no noteworthy side effects in the cases treated intratumorally except for fever occurring in one patient. In the patients treated intravenously, however, fever, general malaise, leukopenia and thrombocytopenia were noted.